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Summary 
Intestinal mucositis is a serious complication of chemotherapy that leads to 
significant morbidity that may require dose or drug adjustments. Specific mitigating 
strategies for mucositis are unavailable, partly due to an incomplete understanding of the 
pathogenic mechanisms. We have previously shown an effect of properdin, a positive 
regulator of complement activation, in models of colitis. Here we use properdin deficient 
(P
KO
) mice to interrogate the role of properdin and complement in small intestinal 
mucositis. Mucositis was induced by 5 daily injections of 5-fluorouracil (5-FU) in wild 
type (WT), P
KO
, IL-10
-/-
 and properdin/IL-10
-/-
 double knockout (DKO) mice. At the time 
of sacrifice their jejunum was collected for histology, immunohistochemistry and 
cytokine and complement activation measurements. Complement became activated in 
mice receiving 5-FU, indicated by increased intestinal levels of C3a and C5a. Compared 
to WT, P
KO
 mice experienced significantly less mucositis, despite C3a levels as high as 
inflamed WT mice and slightly less C5a. On the other hand, P
KO
 mice had higher 
intestinal levels of IL-10. IL-10 expression was mainly by epithelial cells in both 
uninflamed and inflamed P
KO
 mice. IL-10
-/-
 mice proved to be highly susceptible to 
mucositis and DKO mice were equally susceptible, demonstrating that a lack of 
properdin does not protect mice lacking IL-10. We interpret our findings to indicate that 
to a significant extent, the inflammation of mucositis is properdin-dependent but 
complement activation independent. Additionally, the benefit achieved in the absence of 
properdin is associated with increased IL-10 levels, and IL-10 is important in limiting 
mucositis.   
Page 32 of 54Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
3 
 
Introduction 
Gastrointestinal mucositis is a frequent and severe side effect of chemotherapy in 
cancer patients. Depending on the dose and type of chemotherapy, between 50-80% of 
the patients suffer from mucositis that results in vomiting, severe diarrhea, and abdominal 
pain
1, 2
. In particular, small intestinal mucositis leads to reductions in the drug dosage and 
delayed treatment that risks compromising the effectiveness of chemotherapy
3,4
. At the 
histological level, small intestinal mucositis is characterized by epithelial cell death, villi 
shortening, crypt damage and leukocyte infiltration
4
. Moreover, intestinal mucositis 
predisposes to infections that can lead to further significant morbidity and mortality
5,6
. 
Despite research into possible drugs to directly mitigate mucositis, none are yet available 
in the clinic, so there remains an urgent need to better understand the underlying 
pathogenic mechanisms to focus the effort
7
.  
  Recent studies using animal models have implicated both the innate and adaptive 
immune systems mechanistically in the inflammation underlying chemotherapy-induced 
mucositis
8-10
. Complement is a crucial component of the innate immune system that can 
lead to inflammation but also modulate the development of the emerging adaptive 
immune response
11,12
, yet a role for complement, particularly the pattern recognition 
receptors of the lectin and alternative pathways, has not been directly explored in 
mucositis. Our understanding is limited to a report where mRNA for proteins belonging 
to the classical and alternative pathway were found up-regulated in intestines of rats 
subjected to irinotecan induced mucositis
13
.  
Properdin, a protein of the alternative pathway, is a positive regulator of 
complement that can initiate and amplify ongoing complement activation
14
. Because the 
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loss of properdin abolishes terminal complement activation in multiple models of 
intestinal injury
15,16
, we thought to use properdin deficient mice to explore the 
contribution of complement to 5-FU induced mucositis. Surprisingly, loss of properdin 
did not abolish terminal complement activation but was associated with reduced 
pathology compared to 5-FU inflamed WT controls. We further demonstrate that the 
protection in the absence of properdin is likely dependent on IL-10. Overall, we establish 
a previously unappreciated complement activation-independent, pro-inflammatory role of 
properdin in this model of intestinal mucositis. 
Materials and Methods 
Mice 
Age and sex-matched wildtype (WT), properdin knockout (P
KO
), IL-10
-/- 
(Jackson 
Laboratories, Bar Harbour, ME) and IL-10/properdin
 
double gene knockout (DKO, 
developed locally) mice, all on the C57BL/6 background and of both sexes, were used. 
Mice had free access to food and water and were housed on wood chip bedding under 
specific pathogen free conditions on a 12-hour dark/light cycle. All animals used were 
Helicobacter negative, assayed by PCR on stool DNA preparations. Helicobacter triggers 
colitis in susceptible strains of mice, including IL-10 gene knockout animals
17
. The 
numbers of mice used in each experiment is indicted in each figure. The experiments 
were undertaken with the approval of the University Committee on Laboratory Animals, 
Dalhousie University, who in turn adjudicate the standards of the Canadian Council on 
Animal Care. 
5-FU induced small intestinal mucositis 
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 Mucositis was induced by administering 5-FU once daily beginning on day 1 to 
either day 3 or 5. PBS injected mice were treated as vehicle controls. The study began 
with optimizing the dose of 5-FU, examining 50, 100 and 200 mg/kg, delivered 
intraperitoneally. The animals’ weight was recorded daily and any mice that reached a 
loss of 20% were immediately sacrificed and were excluded from the data analyses. In 
some experiments, 5-FU injected WT mice were orally gavaged with the selective C5a 
receptor (C5aR1) antagonist PMX205
(15)
 (200µg/mouse) or water (control) daily from 
day 1 to day 5. One day after the final injection of 5-FU, a stool specimen was collected 
and a rectal bleeding score was assigned based on stool consistency and whether blood 
was detectable, with the scale ranging from 0 (normal stool with no blood) to 4 (diarrhea 
with blood). The mice were then anaesthetized and blood was withdrawn by cardiac 
puncture and serum was isolated. Then the mice were killed by cervical dislocation; their 
jejunum was excised, flushed with cold PBS, opened longitudinally and divided into two 
parts. One longitudinal part was used for histology whereas the other part was 
homogenized. 
Histopathology 
 The longitudinal strip of jejunum was fixed in buffered formalin overnight, 
rehydrated in 70% v/v ethanol, embedded in paraffin, and 4µm sections were stained 
using hematoxylin and eosin. A pathologist blinded to the treatments determined the 
inflammation score summed from the following parameters, villous shortening (0 – 
normal, 1 – mild blunting, 2 – marked blunting), apoptosis (0 – none, 1- focal, 2 - 
diffuse), epithelial damage (0 – normal, 1 – reactive epithelial change, 2 – superficial 
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erosion, 3 - ulceration), inflammation (0 – none, 1 – mild, 2 – moderate, 3 – severe) and 
crypt loss (0 – none, 1 – focal, 2 - diffuse). 
 ELISA measurements 
The remaining longitudinal strip of the jejunum was homogenized in 50mM 
HEPES buffer supplemented with soy trypsin inhibitor (100µg/ml) and centrifuged at 
16000xg for 30 min at 4ºC after which the supernatants were stored at -80°C until 
examined by ELISA. IFN-γ, IL-1β and IL-10 concentrations were measured using ELISA 
kits from eBiosciences (San Diego, CA). C3a and C5a levels were assessed using 
reagents from BD Pharmingen (Mississauga, ON). IL-4 and IL-6 were measured using 
ELISA kits from Peprotech (Dollard, QC). All the protocols were performed according to 
the manufacturer’s instructions. 
Immunohistochemistry 
Four-micron thick paraffin embedded sections were deparaffinised in xylene and 
graded ethanol washes. To detect neutrophils, antigen retrieval was performed by heat in 
10mM sodium citrate buffer (pH=6.0) and the slides incubated with rat anti-mouse Ly6G 
(1:4000, BD Pharmingen). For the detection of IL-10, antigen retrieval was performed by 
heating in Tris-EDTA buffer (pH=6.0) and sections were subsequently incubated with a 
blocking buffer (2% goat serum, 1% BSA, 0.1% triton X-100, 0.05% Tween 20 and 
0.05% sodium azide in PBS) for 1 hour at room temperature (RT) to block non-specific 
binding sites. Tissue sections were then incubated with rat monoclonal anti-mouse IL-10 
antibody (clone JES5-2A5, Abcam, Cambridge, MA) as the primary antibody. Goat anti-
rat IgG secondary antibody was used to detect the primary antibodies. Isotype specific 
control monoclonal antibodies and tissues from IL-10
-/-
 mice were used to confirm the 
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specificity of the staining. Positively stained cells were counted in the remaining intact 
villi only. 
Statistical Analyses  
Statistical analyses were performed using GraphPad Prism version 5 (La Jolla, 
CA). Parametric data are shown as mean ± standard deviation and were compared using 
two-tailed t-test (two groups) or one-way ANOVA with Tukey’s multiple comparison-
post test (more than two groups). Body weights were compared using two-way ANOVA 
with Bonferroni post hoc tests. Inflammation scores are shown in scatter plots with the 
median as a line. Differences between groups were tested using the nonparametric Mann-
Whitney test.  The threshold for declaring a significant difference was defined as p ≤ 
0.05. 
 
Results 
Titration of 5-fluorouracil induced mucositis in mice 
In a pilot experiment to determine a dose of 5-FU for the study, WT mice were 
injected intraperitoneally with 50, 100 or 200 mg/kg/day or PBS for 5 days then 
sacrificed 24 hours later (day 6). All mice receiving 5-FU lost weight in the period of the 
experiment. The average maximum body weight loss in mice receiving 50 and 
100mg/kg/day 5-FU was 10% and 19% respectively (Figure 1A). Mice treated with 
200mg/kg lost close to 20% body weight by day 5 and were sacrificed and this dose was 
not considered further, nor were mice which reached this unintended endpoint used in 
any further data sets.  
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As another macroscopic measure of the treated animals’ phenotype, the stool 
consistency was evaluated on day 6. PBS injected WT mice had firm fecal pellets and no 
rectal bleeding. 5-FU treatment resulted in soft stool pellets and blood in the stool with 
the rectal bleeding score higher in the 100mg/kg group compared to PBS controls (Figure 
1B). Microscopic examination of the small intestines of mice treated with 100mg/kg 5-
FU revealed extensive epithelial damage, crypt loss and villi shortening, and an 
inflammation score statistically higher in 100 mg/kg 5-FU treatment group compared to 
the 50mg/kg group and/or PBS treated controls (Figures 1C and D). Based on these 
clinical and histopathological responses the 100mg/kg 5-FU dose was chosen for 
experiments including the P
KO
 mice. 
Genetic deficiency of properdin ameliorates 5-FU induced intestinal mucositis 
To evaluate whether properdin, and complement, play a role in our model of 
mucositis we compared the response of WT and P
KO
 mice to the 100mg/kg 5-FU 
treatment regimen. Shown in Figure 2A, 5-FU treatment led to comparable body weight 
losses in the two genotypes. Despite weight loss, P
KO
 mice had significantly less rectal 
bleeding compared to the WT mice (Figure 2B). Consistent with the bleeding score data, 
5-FU inflamed P
KO
 mice also experienced significantly lower inflammation scores 
compared to inflamed WT mice (Figures 2C and D). Noteworthy, despite the lower 
inflammation score in P
KO
 mice, the numbers of neutrophils infiltrating the small 
intestine was not different between the strains (Figure 2E). In addition to neutrophil 
infiltration, a reduction in goblet cell numbers is another hallmark of intestinal 
mucositis
18,19
. We stained tissue sections with periodic acid Schiff stain to enumerate 
goblet cells. The two untreated mouse strains had similar numbers of small intestinal 
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goblet cells and while both experienced a reduction in numbers with 5-FU treatment 
(Figure 2F), inflamed P
KO
 mice registered significantly higher numbers compared to 
inflamed WT controls. Thus the preservation of goblet cell numbers in P
KO
 mice was 
associated with the evidence for reduced inflammation. Overall these results indicate that 
P
KO
 mice have an attenuated inflammatory phenotype in 5-FU induced small intestinal 
mucositis. 
Reduced mucositis in properdin deficient mice is C5a independent 
Because properdin is a positive regulator of complement activation we measured 
complement activation products, C3a and C5a, in the intestinal homogenates of treated 
mice. C3a and C5a were detectable at comparable levels in uninflamed mice of both 
strains (Figures 3A and B). 5-FU treated WT mice possessed significantly higher levels 
of C3a and C5a compared to uninflamed controls, confirming that complement is 
activated during mucositis (Figures 3A and B). Interestingly, in inflamed P
KO
 mice the 
increase in C3a levels reached statistical significance but the level of C5a did not, 
suggesting that perhaps reduced levels of C5a were mechanistically responsible for the 
lower inflammation in P
KO
 mice (Figure 3B). Also, considering that we recently 
discovered that properdin impacts the inflammation in murine infectious colitis in a C5a-
dependent mechanism
15
, we sought to elucidate whether C5a is inflammatory in 
mucositis. We gavaged 5-FU inflamed WT mice with the selective C5aR1 antagonist, 
PMX205. Shown in Figures 3C and D, PMX205 treatments did not protect the mice from 
mucositis, suggesting that the apparent lower levels of C5a in P
KO
 mice is not 
mechanistically contributing to the protection. Together these data suggest that while 
properdin in involved in driving mucositis, it is independent of complement activation. 
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Reduced mucositis in P
KO
 mice is associated with higher IL-10 levels 
To further decipher the mechanism behind the protection observed in P
KO
 mice, 
we measured a number of relevant pro- and anti-inflammatory cytokines in intestinal 
homogenates. IFN-γ, IL-6, IL-17A, IL-12 and IL-13 were all below the limit of detection 
in all groups of mice. IL-1β, while detectable, was neither increased nor statistically 
different between the inflamed groups (Figure 4A). With regards to IL-10, 5-FU inflamed 
WT mice demonstrated significantly reduced levels compared to uninflamed mice. On 
the other hand, IL-10 levels were not significantly different comparing inflamed and 
control P
KO
 mice (Figure 4B).  
Since the level of IL-10 was similar between uninflamed and inflamed P
KO
 mice 
and uninflamed WT mice, we used an immunohistological approach to identify the 
cellular source of IL-10, particularly to determine whether the source changes when the 
animals received 5-FU. Tissue sections stained with an anti-IL-10 antibody revealed that 
epithelial cells were the predominant source of IL-10 in healthy animals of both strains 
(Figure 5A). Importantly, and consistent with the ELISA data and the idea that resident 
cells remained the principal source of IL-10, the number of epithelial cells positive for 
IL-10 was significantly higher in 5-FU inflamed P
KO
 mice compared to inflamed WT 
(Figure 5B). Taken together, lower mucositis in P
KO
 mice is associated with higher 
numbers of epithelial cells preserved in the intestine synthesizing IL-10. This finding can 
be explained by a lack of inflammation in the P
KO
 strain receiving 5-FU, leaving more of 
the epithelium intact, and importantly, implicating properdin in triggering the 
inflammation. 
Protection from mucositis is IL-10 dependent in properdin deficient mice 
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IL-10 is a potent anti-inflammatory cytokine in multiple models of intestinal 
inflammation but a role for IL-10 specifically during 5-FU induced mucositis has not 
been reported. Consequently, we conducted experiments to explore the properdin/IL-10 
relationship in our model. If properdin and IL-10 are linked mechanistically, a lack of 
properdin will not protect IL-10
-/-
 mice from mucositis and properdin/IL-10 double 
knockout mice (DKO) will presumably experience similar mucositis as IL-10
-/-
 mice. In 
preliminary experiments treating IL-10
-/- 
mice with 5-FU the animals reached the weight 
loss endpoint early and had to be euthanized, indicating this strain is considerably more 
sensitive than WT to 5-FU (data not shown). Consequently, the 5-FU regimen was 
shortened to 3 days and the mice sacrificed 24 hours later (day 4). Despite the shorter 
treatment regime, significantly higher weight loss was observed in both IL-10
-/-
 and DKO 
mice compared to WT controls (Figure 6A). When combined with IL-10 deficiency the 
protective effect of properdin deficiency was lost, as the inflammation in DKO mice was 
comparable to 5-FU treated IL-10
-/-
 and higher than WT mice (Figure 6B, C). This 
outcome indicates that a lack of properdin fails to protect DKO animals from mucositis, 
and points to the importance of IL-10 in protecting the intestine from mucositis.  
 
Discussion 
Complement is understood to be inflammatory yet the history of investigation into 
complement and mucositis is scant. Bowen et. al surveyed changes in gene expression in 
the intestines of rats subjected to a single injection of irinotecan leading to mucositis and 
found that levels of mRNA for C1q and C2 of the classical pathway and factor D of the 
alternative pathway were considerably increased
13
. Whether the increase in mRNA of 
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complement proteins was a direct product of damaged epithelial cells, infiltrating 
leukocytes, or indirectly triggered by the inflammation (many complement proteins are 
acute phase reactants) or whether the complement was mechanistically involved in the 
pathogenesis of mucositis were not assessed. Here we report that complement indeed 
becomes activated during mucositis but the mechanism by which the genetic deficiency 
of properdin protects against mucositis is complement activation independent. We did 
determine that C5a is not driving mucositis since the C5aR1 antagonist failed to prevent 
inflammation; however, other split complement molecules such as C3a remain to be 
assessed. 
Complement is a network of approximately 30 proteins that coordinate a cascade 
of enzymatic reactions ultimately generating opsonins, the anaphylatoxins and the 
membrane attack complex (MAC). The past understanding was that these activation 
products presumably positively impact the phenotype of inflammatory diseases, not 
limited to the intestines. However, a new understanding is emerging that these proteins, 
particularly the proximal activators in the cascade, have activities independent of 
complement activation. For example, mannose binding lectins (MBL), initiators of the 
lectin pathway, can modulate LPS mediated secretion of IL-8, IL-6 and MCP-1 without 
activating complement
22
. MBL binds the extracellular domain of TLR4 diminishing 
binding of LPS
23
. Properdin was recently shown to facilitate removal of apoptotic cells in 
a complement activation independent manner
24
. Here we demonstrate that the lack of 
properdin did not significantly impact complement activation apart from slightly lower 
C5a levels, yet protected mice from 5-FU injury. As C5a is a potent inflammatory 
product of complement activation, we thought to directly test the impact of C5a in the 
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model. We determined that C5a was not driving the inflammation by administering a 
C5aR1 antagonist, PMX205, which failed to protect WT mice from mucositis. 
Noteworthy, we showed previously that PMX205 significantly reduced DSS-induced 
colitis, indicating that perhaps complement/C5a has different impacts on the large versus 
small intestine
25
. Additionally, the finding that C5a does not influence mucositis only 
strengthens our conclusion that properdin is a positive regulator of mucositis in a 
complement activation independent manner. How properdin positively contributes to 
inflammation consequential to the cell injury caused by 5-FU remains to be discovered. 
IL-10 has profound anti-inflammatory effects in the gastrointestinal tract, clearly 
demonstrated by the fact that a lack of IL-10 or the IL-10 receptor indisputably 
predisposes to colitis, both in experimental animal models and humans. In cancer 
patients, IL-10 levels were found to negatively correlate with the degree of mucositis
27
 
and LPS/IFN-γ stimulated monocytes from patients with high grade mucositis produced 
less IL-10 compared to patients without mucositis
27
. These observations may mean that 
individuals who make less IL-10 experience worse mucositis or alternatively, that events 
related to mucositis may actively suppress IL-10 production. We observed a significant 
reduction in the number of IL-10 producing cells and the soluble IL-10 levels in WT 
mice with mucositis. Using mice deficient in IL-10 we can further address whether 
homeostatic levels of IL-10 provide any initial barrier to mucositis
28
. We further show 
that IL-10 in the small intestine is mainly detectable in epithelial cells, including in P
KO
 
mice (proving this strain is not IL-10 deficient), suggesting local constitutive expression 
of IL-10 plays a role in limiting the cell injury directly due to 5-FU, and that the lack of 
properdin interrupts the subsequent inflammatory response. When both molecules are 
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absent the extent of cell injury overwhelms the properdin-dependent process or provokes 
an alternate mechanism leading to inflammation, and severe mucositis. We are currently 
investigating how IL-10 may directly prevent the apoptosis triggered by 5-FU in gut 
epithelium. Ultimately, the fact that DKO mice were as severely affected by 5-FU as IL-
10
-/-
 mice mechanistically links these two molecules in mucositis.  
Knowing constitutive gut IL-10 levels are not elevated in P
KO
 mice is important 
because there are precedents that indicate the lack of properdin may result in increased 
IL-10. In one example, P
KO
 mice with zymosan induced peritonitis demonstrated higher 
levels of IL-10
29
. Properdin is composed of thrombospondin repeats type I and it possibly 
has activities in mucositis similar to other members of this protein family
30
. In this 
regard, thrombospondin I (also contains type I repeats), negatively regulates the 
production of IL-10 from dendritic cells through interactions with CD47 and CD36
31
. It 
remains to be determined in our model whether properdin uses these or other receptors to 
influence production of IL-10 in the small intestine and inflammation, but currently our 
understanding is that properdin deficiency compromised inflammation, leaving a greater 
number of epithelial cells intact and making IL-10. 
Although our data support the conclusion that PKO mice have normal levels of 
IL-10, it is possible that IL-10
-/-
 mice may have abnormal levels of properdin, where high 
properdin levels would presumably make the mice more susceptible to mucositis. While 
we did not measure properdin levels in the IL-10
-/-
 strain, we interpret our earlier 
experiments exploiting this strain’s susceptibility to colitis to infer there is no obvious 
reason to believe they have high levels of properdin
16
. 
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Despite incomplete knowledge of the mechanisms, our findings identify properdin 
as a potential target for ablating mucositis, particularly considering the lack of impact 
properdin has on complement activation. Complement is required for controlling the 
escape of microbes from inflamed intestines
32
 and this will presumably be intact in 
patients in which properdin levels are intentionally reduced. Properdin is present in very 
low levels in plasma (4-25µg/ml) so purposely reducing levels may be easily 
achievable
33
.  
Our study is the first experimental evidence for a mechanistic role of a 
complement protein during small intestinal mucositis, though not acting through the 
presumed role of supporting complement activation. We do demonstrate that the 
protective effects of properdin deficiency is linked to IL-10. Now, in addition to further 
investigations into the mechanisms of properdin dependent mucositis, experiments are 
needed to assess the impact of properdin on tumor progression and chemotherapeutic 
efficacy against tumors before reducing levels could be applied to mitigate mucositis in 
humans. 
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Figure legends 
Figure 1: 5-FU titration and clinical illness and histopathological phenotypes in WT 
mice. Mice were administered 5-FU daily, to day 5, then were sacrificed 24 hours after 
the final injection. (A) Each animal’s weight was measured daily and is reported as the 
average percentage of the weight from the start of the treatments. Data is shown as mean 
± S.E.M (n=3 mice/group). * and † represent comparison of 50 and 100mg/kg groups 
with no 5-FU controls on the same day, respectively. § is indicative of a difference 
between 50 and 100mg/kg groups. * p<0.05, **p<0.01, ††p<0.01, †††p<0.001 and 
§§p<0.01. (B) Rectal bleeding scores.  Each dot represents a single mouse and the line 
represents the median score. Any animal whose weight loss reached 20% was not 
included in further data collection or analyses. (C) Representative images of the jejunum 
prepared from PBS or 5-FU treated mice. Jejunum of mice receiving 5-FU at a dose of 
100mg/kg demonstrated severe villus height shortening, epithelial damage, crypt loss and 
inflammation. (D) The total inflammation scores were calculated based on criteria 
outlined in the methods. Each dot represents a single mouse and the line represents the 
median inflammation score. *p<0.05 comparing the 50 versus 100 mg/kg groups. 
Figure 2: Properdin deficiency protects mice from 5-FU induced mucositis. (A) 
Weight loss during 5-FU treatments. Data is the mean percent of each animals’ weight at 
the start of the experiment  ± S.E.M (n=6 mice/group). (B) Inflamed P
KO
 mice registered 
significantly less rectal bleed and (C, D) intestinal inflammation, compared to WT mice. 
Each dot represents a single mouse and the line represents the median score. *p<0.05 vs 
inflamed WT mice. (E) Neutrophil infiltration into the5-FU treated mouse intestine. 
Similar numbers of neutrophils were detected in the two strains. (F) PAS positive cells/10 
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intact villi/section and averaged for all mice within a treatment group. The data is the 
mean ± S.E.M of 4-5 mice. 
Figure 3: Reduced inflammation in P
KO
 mice is independent of complement 
activation. Levels of (A) C3a and (B) C5a measured by ELISA in tissue homogenates of 
uninflamed and inflamed mice. Data is shown as mean ± S.E.M (n=3-10 mice/group). 
*p<0.05 and **p<0.01 vs control, ns = not significant. Control refers to mice that did not 
receive 5-FU. To investigate the role of C5a during mucositis, 5-FU inflamed WT mice 
were gavaged with PMX205 or water. All  mice received 5-FU, control refers to mice 
which received water in their gavage. (C) Inflammation and (D) rectal bleeding score of 
control or mice receiving PMX205. Each dot represents a single mouse and the line 
indicates the median score. 
Figure 4: Reduced inflammation in P
KO
 mice is associated with higher IL-10 levels. 
Tissue homogenates from the jejunum of control (did not receive 5-FU) or 5-FU treated 
mice were examined for (A) IL-1β and (B) IL-10.  
Figure 5: IL-10 expression is detected in the epithelium. Control in the figure refers to 
mice which did not receive 5-FU. (A) Immunohistochemical staining for IL-10 shows 
that IL-10 expression on epithelial cells was reduced in inflamed WT but not P
KO
 mice. 
Isotype (control) antibody or anti-IL-10 used on sections from IL-10
-/-
 mice did not 
demonstrate any staining (not shown). (B) Quantification of IL-10 positive epithelial 
cells/10  crypts or villi (shown separately). Cells were counted from intact villi/crypts 
only. Data is shown as mean ± S.E.M (n=4-5 mice/group). *p<0.05 and **p<0.01.  
Figure 6: P
KO
 mice lacking IL-10 are not protected against intestinal mucositis. To 
assess if IL-10 contributes to the protection observed in P
KO
 mice against mucositis, P
KO
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mice were crossed with IL-10
-/- 
and DKO offspring were subjected to 5-FU mucositis. 
WT, IL-10
-/-
 and DKO were administered 5-FU from day 1 to day 3 and sacrificed 24 
hours later. All the mice in the figure received 5-FU. (A) Weight loss during 5-FU 
treatments. Data is shown as mean± S.E.M (n=4 mice/group) and (B) rectal bleed and (C) 
inflammation scores of the mice. Each dot represents a single mouse and the line 
represents the median score. *p<0.05, **p<0.02 versus WT control. 
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